Published in: Cancer Letters
Authors: Hiroshi Fukushima, Seiichiro Takao, Aki Furusawa, Vladimir Valera Romero, Sandeep Gurram, Takuya Kato, Shuhei Okuyama, Makoto Kano, Peter L. Choyke, Hisataka Kobayashi
Enfortumab vedotin (EV), an antibody-drug conjugate (ADC) that targets Nectin-4, has shown promising results in the treatment of bladder cancer. The study investigated use of Nectin-4 targeting photoimmunotherapy in preclinical bladder cancer models. ML7710 was used as light source for activating the therapy in vitro and in vivo.